ESMO
cancer treatment optimization
NICHE-2 trial
SWOG S1801 trial
IPSOS trial
oncology research
Research Highlights In The News From ESMO
Summary
- The ESMO 2022 Congress took place in Paris in September 2022, with around 29,000 delegates, including 5,000 online participants.
- The program featured a broad range of topics, including clinical trial results, translational studies, and health policy initiatives.
- A key theme discussed was the optimization of treatment for patients with locally advanced, resectable cancers.
- The phase II NICHE-2 trial showed that neoadjuvant treatment with ipilimumab plus nivolumab was safe and effective in non-metastatic mismatch repair-deficient colon cancer, with no disease recurrence after a median follow-up of 13 months.
- The phase II SWOG S1801 trial demonstrated that neoadjuvant pembrolizumab improved event-free survival and overall survival in patients with stage IIIB–IV melanoma.
- The phase III IPSOS trial found that atezolizumab extended overall survival and reduced adverse events in patients with non-small-cell lung cancer (NSCLC) without actionable driver alterations, compared to standard chemotherapy options.
In September 2022, the ESMO 2022 Congress was held in Paris, marking the return of a highly anticipated annual in-person event for the oncology community. The conference attracted 29,000 delegates, with approximately 5,000 joining the event online.
The congress featured a diverse program, carefully curated by the programme committee to include a wide range of topics such as clinical trial results, translational studies, and health policy initiatives. The three Presidential Symposia exemplified the variety of themes explored during the event, with a significant focus on optimizing treatment for patients with locally advanced, resectable cancers.
Click for Source
ESMO, cancer treatment optimization, NICHE-2 trial, SWOG S1801 trial, IPSOS trial, oncology research
